Wednesday, September 29, 2021

Pheochromocytomatosis

Most people probably have not heard of the term “pheochromocytomatosis.” Pheochromocytoma itself is already an odd word, let alone pheochromocytomatosis. The more I practice medicine, the more evident is to me that a disease’s presentation and natural history could be affected by medicine itself. Even 30 years ago, pheochromocytoma was still mostly suspected based on clinical symptoms; with the wide use of imaging, most cases of pheochromocytoma nowadays are found incidentally by imaging. Pheochromocytomatosis is likely a modern phenomenon associated with laparoscopic adrenalectomy.   

A pheochromocytoma is surrounded by a fibrous capsule. During a surgical operation, the surgeon separates the pheochromocytoma from the normal tissue and organs and removes the tumor with the capsule intact, so that no tumor is left behind. That usually did not pose a problem in the era of open operation to remove the pheochromocytoma. During a laparoscopic operation, inexperience in surgical skills or accidents can result in rupture of the capsule and tumor cell spillage into the abdomen. The spilled tumor cells can form numerous tiny tumors that may grow to a few centimeters, which is called pheochromocytomatosis. It is not clear how often tumor capsule rupture occurs during adrenalectomy and how often pheochromocytomatosis occurs in those with tumor capsule rupture.

Once pheochromocytomatosis happens, it becomes an incurable problem. Pheochromocytomatosis, however, is indolent and may manifest itself years after the original operation. As pheochromocytomatosis is very rare, we are not sure how to best control it. Reoperation is usually done to remove visible gross tumors. Patients are then monitored. If the tumors grow again, MIBG radiotherapy or PRRT can be tried. If the tumors are still growing after the radiotherapies, somatostatin analogs and other agents may be used.


Dr. Pheo

Wednesday, September 30, 2020

Telemedicine for pheo

I hope everyone has been as safe and healthy as possible during the COVID-19 pandemic!

During the early days of the pandemic, I saw most patients by telemedicine in the form of a video visit. I did see quite a few pheo patients by telemedicine as well. My experience with telemedicine for pheo patients and my interaction with readers on this blog convince me that pheo is the model disease for telemedicine.

As physical examination, a key part of patient visit, rarely contributes to the diagnosis and treatment of pheo, telemedicine for pheo does not lose much compared with traditional patient visit. History taking and review of laboratory test results and imaging studies are the same in telemedicine and in traditional patient visit. The time and cost saved by telemedicine on the patient’s part can be tremendous. With telemedicine, a patient can access a pheo expert much more easily even if the expert is in another city.

Of course, nothing can replace the personal touch, the body language, and the many subtle details during an in-person visit. For the purpose of pheo diagnosis and treatment, however, the convenience of telemedicine offsets its shortcomings. Many of my colleagues feel that telemedicine will be here to stay as an important alternative to in-person visit. For patients with suspected or known pheo, telemedicine will continue allowing them to access pheo experts not locally available.

Dr. Pheo

Friday, November 29, 2019

Why are the repeat test results different?


Happy Holidays!

For a serious diagnosis like pheo, repeat testing of pheo markers is generally a good idea. Pheo test results from the same patient even within a few days or weeks can be quite different at times. Patients having acute illness, anxiety attack, or any emotional or physical stress would have higher pheo marker levels than when they are healthy and restful. The position (sitting or lying) of patients getting blood draw matters. Random variations are always possible. Laboratory errors do happen as well. If the two test results are concordant (which fortunately are more common), we can confidently say whether the patient has normal or abnormal pheo marker levels. If, however, the two test results are discordant (one abnormal and one normal, or one very high and one only slightly high), what shall we do?

There are several factors to consider. First, we need to see the quantitative differences between the two results. If one result is in the high normal range and the other slightly abnormal, they are essentially similar and concordant results. Second, we need to delve into the details on the patient’s mental and physical condition when the tests are done. If the patient is seriously ill when one test is taken, the result is likely higher and does not necessarily suggest pheo. Third, we need to ask ourselves the likelihood of this patient’s having pheo is high or not, based on the grounds why we test for pheo in the first place. Of course the more suspicion we have, the more likely the abnormal result is true. Fourth, past research has shown that if there are no laboratory errors, a single normal test result rules out pheo in most patients. Thus a negative pheo test result should be given more weight in general. Last, when we are really not sure, imaging is needed to give us more information.

Dr. Pheo

Tuesday, March 19, 2019

Ten years and going strong!

I started the Dr. Pheo blog on March 19, 2009. At that time, I was not certain how long the blog would last. Today, exactly 10 years later, I am pleased to see the blog is still going and going strong! I thank my family, friends, colleagues, patients, and especially readers for your support and encouragement in all these years.
      Pheo is a fascinating but challenging disease. In the last 10 years, we witnessed the explosive growth in pheo genetics and pathogenesis. Genetic tests for pheo are now widely available. We also observed the unraveling of the natural history of pheo and the understanding of pheo-induced heart problems. More doctors now recognize that small pheos exhibit features distinct from those of large pheos. The diagnosis of pheo progressed right in front of our eyes. Metanephrines are now accepted by most doctors as the best tests and are more available world-wide. The imaging characteristics of pheo were firmly established with the emergence of many nuclear imaging tools. In spite of the advancements, two major challenges still face us: misdiagnosis of pheo and management of malignant pheo.
      I will continue the blog as long as I can. I will remain anonymous.  
   
Dr. Pheo

Tuesday, March 5, 2019

Plasma or urine metanephrines?

I have discussed plasma versus urine metanephrines in the past. Recently a few doctors asked me this question again. I figure that if some doctors are not clear whether to order plasma or urine metanephrines, patients probably also want to know the pros and cons of plasma and urine metanephrines.
      First of all, both tests are great. If your local area only offers one of them, take it. If your local area offers both tests, which one is better? Shall you do both? My personal preference is plasma metanephrines. The plasma test is convenient and can be done to any patient at any time. The only small drawback is the blood draw itself. If you really hate needles, the plasma test could be an issue. The urine test offers no practical advantage over the plasma test. In theory and in earlier reports, the urine test is less prone to false positive results. In real clinical practice, the urine test and the plasma test perform similarly. The urine test is laborious to collect (24-hour urine is required), not reliable in patients with kidney problems, and hard to do in children. Lastly, the urine test results have to be corrected by urine creatinine. I have seen patients who passed ~5 liters of urine in 24 hours; of course the metanephrines levels are higher simply because of the large urine volume. The results usually are more accurate after they are divided by the total amount of creatinine in the urine. Again I want to emphasize that I personally don’t see why one would need the urine metanephrines for pheo diagnosis if plasma test is available. There is also no need to do both tests.
       
Dr. Pheo

Saturday, July 28, 2018

In case I missed your questions...

Only a few days ago, did I realize that I had missed several questions from the Dr. Pheo blog. I have not received any email alerts on new questions since late May 2018. Initially I thought perhaps it was summer time or perhaps readers found answers from previous posts. Then I saw a few comments on the blog a few days ago. That was strange because I was supposed to get email alters on new comments. I certainly did not change any settings and I checked again and found all the settings were the same.

Then I googled the problem. Wow, so many other bloggers had similar problems. It looked like Google Blogger required bloggers to re-consent receiving email alerts. The bottom line is that I can now receive email alerts of your questions. If you posted questions in late May or after, and did not receive answers from me, please post your questions again if you still need the answers.

Dr. Pheo

Thursday, June 28, 2018

Incidental pheo (?) found by DOTATATE PET

Whenever a new imaging method is used widely, incidental findings from it are encountered. The new Ga-68 DOTATATE PET is no exception. It is well known that DOTATATE signals are normally found in the pituitary, salivary glands, thyroid, liver, spleen, and adrenal glands. Some people may also have signals in the pancreas.
      Although the adrenal glands are known to be lit up by DOTATATE PET, the signal from normal adrenal glands is usually low. A technical jargon called the standard uptake value (SUV) quantitatively describes the intensity of PET signals. Unfortunately, different machines give out different SUVs on the same organ of the same patient. The SUV thus has relative importance only in the same patient using the same machine.
      I saw a patient recently. She had another kind of neuroendocrine tumor and did a DOTATATE PET. The PET showed she had strong signal on one adrenal gland (SUV ~8) while the other adrenal gland had normal signal (SUV ~2). CT showed a tiny nodule in the adrenal gland with strong PET signal. Is this a metastatic lesion of the other neuroendocrine tumor? Or is it a tiny pheo that is incidentally found by the DOATATE PET? Either adrenal metastasis from neuroendocrine tumor or pheo is rare. Based on a variety of factors, I favor she has a tiny pheo. There are no convincing ways to prove either diagnosis. Only time will tell.

Dr. Pheo